Old West Investment Management LLC Purchases Shares of 393,782 Elanco Animal Health Incorporated (NYSE:ELAN)

Old West Investment Management LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 393,782 shares of the company’s stock, valued at approximately $4,769,000. Elanco Animal Health accounts for about 1.9% of Old West Investment Management LLC’s portfolio, making the stock its 19th largest holding. Old West Investment Management LLC owned approximately 0.08% of Elanco Animal Health as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in ELAN. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health during the third quarter valued at approximately $35,000. Jones Financial Companies Lllp boosted its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its stake in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in Elanco Animal Health during the fourth quarter worth $61,000. Finally, Blue Trust Inc. lifted its holdings in shares of Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after acquiring an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 5.7 %

NYSE:ELAN opened at $9.17 on Friday. The stock’s fifty day moving average price is $11.04 and its two-hundred day moving average price is $12.30. The company has a market cap of $4.55 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52-week low of $8.80 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.57% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on ELAN. Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus dropped their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Barclays reduced their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. UBS Group decreased their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Finally, Morgan Stanley cut their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.